11 recruiting. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Recruiting 11 |
Follow Cardiovascular Abnormalities: new trials by email Literature Review of Cardiovascular Abnormalities trials Research Report on Cardiovascular Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial in Patients With Barth Syndrome- 4TAZPower Elamipretide, Placebo - Barth Syndrome | Phase 4 | Recruiting | Stealth BioTherapeutics Inc. | 48 | 2026-07-02 | 2026-09-17 |
| The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy - Fontan, Heart Failure | Phase 4 | Recruiting | The University of Hong Kong | 30 | 2026-07-01 | 2026-07-28 |
| A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy Sotatercept, vasodilator-based PAH therapy - Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease | Phase 4 | Recruiting | Kazuya Hosokawa | 36 | 2025-10-07 | 2026-01-21 |
| Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU) Livmarli Oral Product - Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | Phase 4 | Recruiting | Mirum Pharmaceuticals, Inc. | 230 | 2025-09-25 | 2026-06-23 |
| Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome Micronized progesterone 200 MG, Micronized Progesterone 100 MG - Turner Syndrome, Primary Ovarian Insufficiency (Poi) | Phase 4 | Recruiting | Children's Mercy Hospital Kansas City | 40 | 2025-07-31 | 2026-08-25 |
| Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial SGLT2 inhibitor (Dapagliflozin 10mg) - Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF) | Phase 4 | Recruiting | The University of Hong Kong | 106 | 2025-05-12 | 2026-10-28 |
| Effect of Dexmedetomidine Supplementation to General Anaesthesia in Paediatric Transcatheter Closure of Atrial Septal Defect Dexmedetomidine, Saline (NaCl 0,9 %) (placebo) - Atrial Septal Defect (ASD), Dexmedetomidine | Phase 4 | Recruiting | Alexandria University | 30 | 2024-04-03 | 2024-10-15 |
| Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome 17-beta estradiol - Turner Syndrome, Hypogonadism; Ovarian | Phase 4 | Recruiting | Aarhus University Hospital | 50 | 2021-11-29 | 2024-08-26 |
| Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome 17-beta estradiol - Turner Syndrome, Hypogonadism; Ovarian | Phase 4 | Recruiting | Aarhus University Hospital | 50 | 2021-11-29 | 2024-08-23 |
| Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery Continuous ketorolac - Congenital Heart Disease in Children | Phase 4 | Recruiting | Phoenix Children's Hospital | 166 | 2021-03-01 | 2026-08-12 |
| The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome methylphenidate, fluoxetin, risperidone - Velocardiofacial Syndrome, Williams Syndrome | Phase 4 | Recruiting | The Chaim Sheba Medical Center | 400 | 2001-05-01 | 2026-03-18 |
Heart Defects, Congenital (3) · Turner Syndrome (3) · Hypogonadism (2) · Agnosia (1) · Alagille Syndrome (1) · Barth Syndrome (1) · Cardiovascular Diseases (1) · Cholestasis (1) · Cholestasis, progressive familial intrahepatic 1 (1) · DiGeorge Syndrome (1) · Eisenmenger Complex (1) · Emergence Delirium (1) · Fractures, Stress (1) · Fragile X Syndrome (1) · Heart Failure (1)
Congenital Abnormalities (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Cardiovascular Diseases (10) · Heart Diseases (10) · Heart Defects, Congenital (8) · Genetic Diseases, Inborn (6) · Chromosome Disorders (4) · Endocrine System Diseases (4) · Sex Chromosome Disorders (4) · Abnormalities, Multiple (3) · Disorders of Sex Development (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Gonadal Disorders (3)
Estradiol (2) · dapagliflozin (2) · estradiol, estriol drug combination (2) · ACE-011 (1) · Dexmedetomidine (1) · Fluoxetine (1) · Methylphenidate (1) · Progesterone (1) · Risperidone (1) · Sodium Chloride (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (1) · maralixibat (1)
Aarhus University Hospital (2) · The University of Hong Kong (2) · Alexandria University (1) · Children's Mercy Hospital Kansas City (1) · Kazuya Hosokawa (1) · Mirum Pharmaceuticals, Inc. (1) · Phoenix Children's Hospital (1) · Stealth BioTherapeutics Inc. (1) · The Chaim Sheba Medical Center (1)
United States (3) · Denmark (2) · Hong Kong (2) · Belgium (1) · Canada (1) · Egypt (1) · France (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Portugal (1) · Spain (1)
Claus H Gravholt, Professor (2) · Chun-Ka Dr Wong, Clinical Assistant Professor (1) · Kevin Engelhardt, MD (1) · Prof Yiu Fai Cheung (1) · Rekha Sathyanarayana (1) · Tazim Dowlut-McElroy, M.D., M.S. (1)
PMID 17572925, PMID 20970202, PMID 26114442, PMID 29222139, PMID 29663436, PMID 31351553, PMID 31535829, PMID 31980166, PMID 33197559, PMID 34405863, PMID 34656466, PMID 35487320, PMID 36171554, PMID 36605072, PMID 37435053, PMID 37615988, PMID 37622666, PMID 38162132, PMID 38430085, PMID 41819579